Sharon Schulzki

Insider

First SEC filing: Feb. 4, 2005 · Latest: Feb. 4, 2005

On this page

Insider at

0 buys (P) 0 sells (S) Net: $0 + 3 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
Feb. 2, 2005	CNSY	A	70,000	—	—	380,000 Direct	+22.58%	Acquired	(price as of 2026-08-20)
June 2, 2004	CNSY	A	50,000	—	—	310,000 Direct	+19.23%	Acquired	(price as of 2026-08-20)
Nov. 3, 2003	CNSY	A	35,000	—	—	260,000 Direct	+15.56%	Acquired	(price as of 2026-08-20)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
Feb. 2, 2005	CNSY	Employee Stock Options	Common Stock (70,000)	$3.10	Feb. 2, 2015	70,000	Acquired
June 2, 2004	CNSY	Employee Stock Options (Rights to Buy)	Common Stock (50,000)	$4.12	June 2, 2014	50,000	Acquired
Nov. 3, 2003	CNSY	Employee Stock Option (Right to Buy)	Common Stock (35,000)	$3.84	Nov. 3, 2013	35,000	Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Matched by name from proxy statements (DEF 14A) — verify against the filing.

President—Marketing & Development—Biomaterials

Fiscal year	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension change	Other	Total
2003	—	—	—	—	—	—	—	—

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.